SCHEDULE: Ting Yang Reports 8.44% Stake in Indaptus Therapeutics

Ting Yang filed an amendment to his Schedule 13D disclosing an 8.44% beneficial ownership stake in Indaptus Therapeutics, Inc. following a dilution event.

Summary

• Ting Yang beneficially owns 11,250,000 shares of Indaptus Therapeutics, Inc. common stock.
• The ownership stake represents 8.44% of the company's total outstanding shares.
• The filing serves as an update due to a decrease in percentage ownership caused by the company's issuance of new shares in a private placement on June 17, 2026.
• The reporting person did not buy or sell any shares during the period; the change in percentage is purely dilutive.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing; the change in ownership percentage is purely a result of corporate dilution rather than a change in the investor's position.

Positives

• The reporting person maintains a significant long-term position of 11,250,000 shares.
• The investment was funded through personal capital, indicating personal conviction in the issuer.

Negatives

• The reporting person's ownership percentage decreased due to the company's recent private placement, reflecting dilution for existing shareholders.

Risks

• Dilution risk remains a factor for existing shareholders as the company continues to issue new equity to fund operations.
• The reporting person's influence is subject to changes in the total outstanding share count of the issuer.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, focusing instead on the reporting person's ownership status.

Industry Context

StockSavvy.ai notes that this filing reflects the common practice of equity dilution in the biotechnology sector, where companies frequently raise capital through private placements to fund clinical development, thereby adjusting the ownership percentages of major stakeholders.

Comparison to Industry Standards

• The reporting of beneficial ownership via Schedule 13D is standard regulatory compliance for investors exceeding the 5% threshold.
• The dilution event is consistent with typical capital-raising activities for clinical-stage biotech firms.

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Existing shareholders experienced dilution due to the June 17, 2026 private placement.

Next Steps

• Continued monitoring of the issuer's share count and potential future equity offerings.

Key Dates

Keywords

Indaptus Therapeutics, Schedule 13D, Ting Yang, Beneficial Ownership, Equity Dilution, Biotech Investment